Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time poi...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/2/925 |
id |
doaj-afe46cd1a3874b7c90cc25b6849e4cdc |
---|---|
record_format |
Article |
spelling |
doaj-afe46cd1a3874b7c90cc25b6849e4cdc2021-01-19T00:05:09ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-01-012292592510.3390/ijms22020925Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Maria A. Papadaki0Ippokratis Messaritakis1Oraianthi Fiste2John Souglakos3Eleni Politaki4Athanasios Kotsakis5Vassilis Georgoulias6Dimitrios Mavroudis7Sofia Agelaki8Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Vassilika Vouton, 71110 Crete, GreeceLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Vassilika Vouton, 71110 Crete, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Vassilika Vouton, 71110 Crete, GreeceLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Vassilika Vouton, 71110 Crete, GreeceDepartment of Oncology, University General Hospital of Larissa, School of Health Sciences, University of Thessaly, 413 34 Larissa, GreeceDepartment of Medical Oncology, IASO General Hospital, 15562 Athens, GreeceLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Vassilika Vouton, 71110 Crete, GreeceLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Vassilika Vouton, 71110 Crete, GreeceWe herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre- and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: <i>p</i> = 0.004), CEACAM5mRNA (<i>p</i> = 0.010), or by any assay (<i>p</i> = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: <i>p</i> = 0.000; overall survival; OS: <i>p</i> = 0.009), CEACAM5mRNA+ CTCs (PFS: <i>p</i> = 0.043; OS: <i>p</i> = 0.039), and CTCs by any assay (PFS: <i>p</i> = 0.005; OS: <i>p</i> = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; <i>p</i> = 0.001) and death (HR: 2.866; <i>p</i> = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (<i>p</i> = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre- and post-treatment was associated with reduced PFS (<i>p</i> = 0.036) and OS (<i>p</i> = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC.https://www.mdpi.com/1422-0067/22/2/925liquid biopsycirculating tumors cellsnon-small cell lung cancerCellSearch systemCEACAM5mRNAprognostic biomarkers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maria A. Papadaki Ippokratis Messaritakis Oraianthi Fiste John Souglakos Eleni Politaki Athanasios Kotsakis Vassilis Georgoulias Dimitrios Mavroudis Sofia Agelaki |
spellingShingle |
Maria A. Papadaki Ippokratis Messaritakis Oraianthi Fiste John Souglakos Eleni Politaki Athanasios Kotsakis Vassilis Georgoulias Dimitrios Mavroudis Sofia Agelaki Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) International Journal of Molecular Sciences liquid biopsy circulating tumors cells non-small cell lung cancer CellSearch system CEACAM5mRNA prognostic biomarkers |
author_facet |
Maria A. Papadaki Ippokratis Messaritakis Oraianthi Fiste John Souglakos Eleni Politaki Athanasios Kotsakis Vassilis Georgoulias Dimitrios Mavroudis Sofia Agelaki |
author_sort |
Maria A. Papadaki |
title |
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_short |
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_full |
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_fullStr |
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_full_unstemmed |
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_sort |
assessment of the efficacy and clinical utility of different circulating tumor cell (ctc) detection assays in patients with chemotherapy-naïve advanced or metastatic non-small cell lung cancer (nsclc) |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-01-01 |
description |
We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre- and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: <i>p</i> = 0.004), CEACAM5mRNA (<i>p</i> = 0.010), or by any assay (<i>p</i> = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: <i>p</i> = 0.000; overall survival; OS: <i>p</i> = 0.009), CEACAM5mRNA+ CTCs (PFS: <i>p</i> = 0.043; OS: <i>p</i> = 0.039), and CTCs by any assay (PFS: <i>p</i> = 0.005; OS: <i>p</i> = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; <i>p</i> = 0.001) and death (HR: 2.866; <i>p</i> = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (<i>p</i> = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre- and post-treatment was associated with reduced PFS (<i>p</i> = 0.036) and OS (<i>p</i> = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC. |
topic |
liquid biopsy circulating tumors cells non-small cell lung cancer CellSearch system CEACAM5mRNA prognostic biomarkers |
url |
https://www.mdpi.com/1422-0067/22/2/925 |
work_keys_str_mv |
AT mariaapapadaki assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT ippokratismessaritakis assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT oraianthifiste assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT johnsouglakos assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT elenipolitaki assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT athanasioskotsakis assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT vassilisgeorgoulias assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT dimitriosmavroudis assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT sofiaagelaki assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc |
_version_ |
1724332638953537536 |